On March 15, 2018 X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, reported that an abstract highlighting X4P-001, the Company’s CXCR4 antagonist, has been selected for presentation at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL (Press release, X4 Pharmaceuticals, MAR 15, 2018, View Source [SID1234524826])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These results demonstrate enhanced immune cell activation and lymphocyte infiltration with X4P-001, alone and in combination with the anti-PD-1 immunotherapy pembrolizumab (Keytruda), in the melanoma tumor microenvironment."
Tweet this
Details of the poster presentation on X4P-001 are as follows:
Poster Title: X4P-001, an oral bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma
Author: Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah
Session: Immune Response to Therapies 1
Abstract #: 613
Date & Time: Sunday April 15, 2018 1:00 PM – 5:00 PM CT
"We are pleased to present these clinical biomarker data from our ongoing Phase 1b clinical study with X4P-001 in patients with melanoma," said Sudha Parasuraman, MD, Chief Medical Officer of X4 Pharmaceuticals. "These results demonstrate enhanced immune cell activation and lymphocyte infiltration with X4P-001, alone and in combination with the anti-PD-1 immunotherapy pembrolizumab (Keytruda), in the melanoma tumor microenvironment."
About X4P-001-IO in Cancer
X4P-001-IO is an investigational selective, oral, small molecule inhibitor of CXCR4 (C-X-C receptor type 4) that regulates the tumor microenvironment thereby enhancing endogenous anti-tumor responses. CXCR4 is a chemokine receptor that modulates immune function and angiogenesis through the trafficking of key immune cells such as T- cells, dendritic cells, and myeloid derived suppressor cells. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO is being investigated in three separate clinical studies in solid tumors.